Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.

A rare condition called Eosinophilic Fasciitis caused a 42-year-old engineer severe pain and stiffness. Doctors identified ...

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ...

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt ...

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...

A new antifibrotic option for patients living with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...

Higher BMI and IBD causally increase hidradenitis suppurativa risk, large study finds, providing actionable insights for ...

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Pharmaceutical Group has received approval from China’s National Medical ...

In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...